<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37761277</PMID><DateRevised><Year>2023</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2075-4418</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>18</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>11</Day></PubDate></JournalIssue><Title>Diagnostics (Basel, Switzerland)</Title><ISOAbbreviation>Diagnostics (Basel)</ISOAbbreviation></Journal><ArticleTitle>IVDR: Analysis of the Social, Economic, and Practical Consequences of the Application of an Ordinance of the In Vitro Diagnostic Ordinance in Switzerland.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2910</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/diagnostics13182910</ELocationID><Abstract><AbstractText>IVDR regulation represents a major challenge for diagnostic microbiology laboratories. IVDR complicates a broad range of aspects and poses a risk given the high diversity of pathogens (including rare but highly virulent microbes) and the large variety of samples submitted for analysis. The regular emergence of new pathogens (including Echovirus E-11, Adenovirus 41, Monkeypox virus, Alongshan virus, and Enterovirus D68, as recent examples in Europe in the post SARS-CoV-2 era) is another factor that makes IVDR regulation risky, because its detrimental effect on production of in-house tests will negatively impact knowledge and expertise in the development of new diagnostic tests. Moreover, such regulations negatively impact the availability of diagnostic tests, especially for neglected pathogens, and has a detrimental effect on the overall costs of the tests. The increased regulatory burden of IVDR may thereby pose an important risk for public health. Taken together, it will have a negative impact on the financial balance of diagnostic microbiology laboratories (especially small ones). The already-high standards of quality management of all ISO-accredited and Swissmedic-authorized laboratories render IVDR law of little value, at least in Switzerland, while tremendously increasing the regulatory burden and associated costs. Eventually, patients will need to pay for diagnostic assays outside of the framework of their insurance in order to obtain a proper diagnostic assessment, which may result in social inequity. Thus, based on the risk assessment outlined above, the coordinated commission for clinical microbiology proposes adjusting the IvDO ordinance by (i) introducing an obligation to be ISO 15189 accredited and (ii) not implementing the IvDO 2028 milestone.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Coste</LastName><ForeName>Alix T</ForeName><Initials>AT</Initials><Identifier Source="ORCID">0000-0001-9481-9778</Identifier><AffiliationInfo><Affiliation>Institute of Microbiology, University of Lausanne &amp; University Hospital Center, 1011 Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Egli</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Medical Microbiology, University of Zurich, 8006 Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schrenzel</LastName><ForeName>Jacques</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Bacteriology Laboratory, Service of Laboratory Medicine, Department of Diagnostic, Geneva University Hospitals, 1211 Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nickel</LastName><ForeName>Beatrice</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-2732-2643</Identifier><AffiliationInfo><Affiliation>Swiss Tropical and Public Health Institute, 4123 Allschwil, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Basel, 4002 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zbinden</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Medical Microbiology, University of Zurich, 8006 Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lienhard</LastName><ForeName>Reto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>ADMed Microbiologie Laboratory, 2300 La Chaux-de-Fonds, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dumoulin</LastName><ForeName>Alexis</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Institut Central des Hôpitaux, Hôpital du Valais, 1950 Sion, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Risch</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dr Risch Medical Laboratory, Wuhrstrasse 14, 9490 Vaduz, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greub</LastName><ForeName>Gilbert</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-9529-3317</Identifier><AffiliationInfo><Affiliation>Institute of Microbiology, University of Lausanne &amp; University Hospital Center, 1011 Lausanne, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Disease Service, University of Lausanne &amp; University Hospital Center, 1011 Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Coordinated Clinical Commission of Microbiology (CCCM)</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Diagnostics (Basel)</MedlineTA><NlmUniqueID>101658402</NlmUniqueID><ISSNLinking>2075-4418</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IVDR</Keyword><Keyword MajorTopicYN="N">consequences</Keyword><Keyword MajorTopicYN="N">microbiology</Keyword><Keyword MajorTopicYN="N">risks</Keyword></KeywordList><CoiStatement>All authors are lab managers active in Switzerland and are impacted by the IvDO. G Greub has a research agreement with Becton-Dickinson on their BD Kiestra lab automated system and is medical advisor of Resistell, a start-up developing a new device for testing antibiotic susceptibility of bacteria. G Greub is also co-director of JeuPRO, a game company distributing games on microbes. A Egli is a medical advisor of two start-up companies, Sefunda and PhAST, both of which are developing rapid pathogen detection assays. However, no authors have a direct conflict of interest with the present position paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37761277</ArticleId><ArticleId IdType="pmc">PMC10529212</ArticleId><ArticleId IdType="doi">10.3390/diagnostics13182910</ArticleId><ArticleId IdType="pii">diagnostics13182910</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>European Union  In vitro Diagnostic regulation. 2017.  [(accessed on 1 July 2023)].  Available online:  https://eur-lex.europa.eu/eli/reg/2017/746/oj.</Citation></Reference><Reference><Citation>The Swiss Federal Council  Ordinance on In Vitro Diagnostic Medical Devices (IvDO) 2022.  [(accessed on 1 July 2023)].  Available online:  https://www.fedlex.admin.ch/filestore/fedlex.data.admin.ch/eli/cc/2022/291/20220526/en/doc/fedlex-data-admin-ch-eli-cc-2022-291-20220526-en-doc.doc.</Citation></Reference><Reference><Citation>Kahles A., Goldschmid H., Volckmar A.L., Ploeger C., Kazdal D., Penzel R., Budczies J., Kempny G., Kazmierczak M. Structure and content of the EU-IVDR: Current status and implications for pathology. Pathologie. 2023:1–13. doi: 10.1007/s00292-022-01176-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00292-022-01176-z</ArticleId><ArticleId IdType="pmc">PMC9896441</ArticleId><ArticleId IdType="pubmed">36735063</ArticleId></ArticleIdList></Reference><Reference><Citation>Bank P.C.D., Jacobs L.H.J., van den Berg S.A.A., van Deutekom H.W.M., Hamann D., Molenkamp R., Ruivenkamp C.A.L., Swen J.J., Tops B.B.J., Wamelink M.M.C., et al. The end of the laboratory developed test as we know it? Recommendations from a national multidisciplinary taskforce of laboratory specialists on the interpretation of the IVDR and its complications. Clin. Chem. Lab. Med. 2020;59:491–497. doi: 10.1515/cclm-2020-1384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2020-1384</ArticleId><ArticleId IdType="pubmed">33554568</ArticleId></ArticleIdList></Reference><Reference><Citation>van Deutekom H.W.M., Haitjema S. Recommendations for IVDR compliant in-house software development in clinical practice: A how-to paper with three use cases. Clin. Chem. Lab. Med. 2022;60:982–988. doi: 10.1515/cclm-2022-0278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2022-0278</ArticleId><ArticleId IdType="pubmed">35538674</ArticleId></ArticleIdList></Reference><Reference><Citation>European Union  Guidance on Classification Rules for In Vitro Diagnostic Medical Devices under Regulation (EU) 2017/746. 2023.  [(accessed on 1 July 2023)].  Available online:  https://health.ec.europa.eu/latest-updates/update-mdcg-2020-16-rev2-guidance-classification-rules-vitro-diagnostic-medical-devices-under-2023-02-10_en.</Citation></Reference><Reference><Citation>Pandey S., Yadav B., Pandey A., Tripathi T., Khawary M., Kant S., Tripathi D. Lessons from SARS-CoV-2 Pandemic: Evolution, Disease Dynamics and Future. Biology. 2020;9:141. doi: 10.3390/biology9060141.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biology9060141</ArticleId><ArticleId IdType="pmc">PMC7344768</ArticleId><ArticleId IdType="pubmed">32604825</ArticleId></ArticleIdList></Reference><Reference><Citation>Desoubeaux G., Coste A.T., Imbert C., Hennequin C. Overview about Candida auris: What’s up 12 years after its first description? J. Mycol. Med. 2022;32:101248. doi: 10.1016/j.mycmed.2022.101248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mycmed.2022.101248</ArticleId><ArticleId IdType="pubmed">35091280</ArticleId></ArticleIdList></Reference><Reference><Citation>Marions L., Rotzen-Ostlund M., Grillner L., Edgardh K., Tiveljung-Lindell A., Wikstrom A., Lidbrink P. High occurrence of a new variant of Chlamydia trachomatis escaping diagnostic tests among STI clinic patients in Stockholm, Sweden. Sex. Transm. Dis. 2008;35:61–64. doi: 10.1097/OLQ.0b013e318141feac.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/OLQ.0b013e318141feac</ArticleId><ArticleId IdType="pubmed">17762244</ArticleId></ArticleIdList></Reference><Reference><Citation>Diene S.M., Bertelli C., Pillonel T., Jacquier N., Croxatto A., Jaton K., Greub G. Comparative genomics of Neisseria meningitidis strains: New targets for molecular diagnostics. Clin. Microbiol. Infect. 2016;22:568-e1. doi: 10.1016/j.cmi.2016.03.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2016.03.022</ArticleId><ArticleId IdType="pubmed">27085725</ArticleId></ArticleIdList></Reference><Reference><Citation>Hraib M., Jouni S., Albitar M.M., Alaidi S., Alshehabi Z. The outbreak of monkeypox 2022: An overview. Ann. Med. Surg. 2022;79:104069. doi: 10.1016/j.amsu.2022.104069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amsu.2022.104069</ArticleId><ArticleId IdType="pmc">PMC9289401</ArticleId><ArticleId IdType="pubmed">35860140</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar N., Acharya A., Gendelman H.E., Byrareddy S.N. The 2022 outbreak and the pathobiology of the monkeypox virus. J. Autoimmun. 2022;131:102855. doi: 10.1016/j.jaut.2022.102855.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2022.102855</ArticleId><ArticleId IdType="pmc">PMC9534147</ArticleId><ArticleId IdType="pubmed">35760647</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen E., Kantele A., Koopmans M., Asogun D., Yinka-Ogunleye A., Ihekweazu C., Zumla A. Human Monkeypox: Epidemiologic and Clinical Characteristics, Diagnosis, and Prevention. Infect. Dis. Clin. N. Am. 2019;33:1027–1043. doi: 10.1016/j.idc.2019.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idc.2019.03.001</ArticleId><ArticleId IdType="pmc">PMC9533922</ArticleId><ArticleId IdType="pubmed">30981594</ArticleId></ArticleIdList></Reference><Reference><Citation>Stegmuller S., Fraefel C., Kubacki J. Genome Sequence of Alongshan Virus from Ixodes ricinus Ticks Collected in Switzerland. Microbiol. Resour. Announc. 2023;12:e0128722. doi: 10.1128/mra.01287-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mra.01287-22</ArticleId><ArticleId IdType="pmc">PMC10019301</ArticleId><ArticleId IdType="pubmed">36779723</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z.D., Wang W., Wang N.N., Qiu K., Zhang X., Tana G., Liu Q., Zhu X.Q. Prevalence of the emerging novel Alongshan virus infection in sheep and cattle in Inner Mongolia, northeastern China. Parasit. Vectors. 2019;12:450. doi: 10.1186/s13071-019-3707-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13071-019-3707-1</ArticleId><ArticleId IdType="pmc">PMC6740026</ArticleId><ArticleId IdType="pubmed">31511049</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertelli C., Greub G. Rapid bacterial genome sequencing: Methods and applications in clinical microbiology. Clin. Microbiol. Infect. 2013;19:803–813. doi: 10.1111/1469-0691.12217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1469-0691.12217</ArticleId><ArticleId IdType="pubmed">23601179</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vries H.J.C., Pannekoek Y., Dean D., Bavoil P.M., Borel N., Greub G., Morre S.A., on behalf ofthe ICSP Subcommittee on the Taxonomy of Chlamydiae Call for consensus in Chlamydia trachomatis nomenclature: Moving from biovars, serovars, and serotypes to genovariants and genotypes. Clin. Microbiol. Infect. 2022;28:761–763. doi: 10.1016/j.cmi.2022.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.02.013</ArticleId><ArticleId IdType="pubmed">35202789</ArticleId></ArticleIdList></Reference><Reference><Citation>Neves A., Walther D., Martin-Campos T., Barbie V., Bertelli C., Blanc D., Bouchet G., Erard F., Greub G., Hirsch H.H., et al. The Swiss Pathogen Surveillance Platform—Towards a nation-wide One Health data exchange platform for bacterial, viral and fungal genomics and associated metadata. Microb. Genom. 2023;9:mgen001001. doi: 10.1099/mgen.0.001001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/mgen.0.001001</ArticleId><ArticleId IdType="pmc">PMC10272868</ArticleId><ArticleId IdType="pubmed">37171846</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillonel T., Bertelli C., Salamin N., Greub G. Taxogenomics of the order Chlamydiales. Int. J. Syst. Evol. Microbiol. 2015;65:1381–1393. doi: 10.1099/ijs.0.000090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/ijs.0.000090</ArticleId><ArticleId IdType="pubmed">25634949</ArticleId></ArticleIdList></Reference><Reference><Citation>Tagini F., Greub G. Bacterial genome sequencing in clinical microbiology: A pathogen-oriented review. Eur. J. Clin. Microbiol. Infect. Dis. 2017;36:2007–2020. doi: 10.1007/s10096-017-3024-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-017-3024-6</ArticleId><ArticleId IdType="pmc">PMC5653721</ArticleId><ArticleId IdType="pubmed">28639162</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanstapel F., Orth M., Streichert T., Capoluongo E.D., Oosterhuis W.P., Cubukcu H.C., Bernabeu-Andreu F.A., Thelen M., Jacobs L.H.J., Linko S., et al. ISO 15189 is a sufficient instrument to guarantee high-quality manufacture of laboratory developed tests for in-house-use conform requirements of the European In-Vitro-Diagnostics Regulation. Clin. Chem. Lab. Med. 2023;61:608–626. doi: 10.1515/cclm-2023-0045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2023-0045</ArticleId><ArticleId IdType="pubmed">36716120</ArticleId></ArticleIdList></Reference><Reference><Citation>Dombrink I., Lubbers B.R., Simulescu L., Doeswijk R., Tkachenko O., Dequeker E., Fraser A.G., van Dongen J.J.M., Cobbaert C., Bruggemann M., et al. Critical Implications of IVDR for Innovation in Diagnostics: Input from the BioMed Alliance Diagnostics Task Force. Hemasphere. 2022;6:e724. doi: 10.1097/HS9.0000000000000724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HS9.0000000000000724</ArticleId><ArticleId IdType="pmc">PMC9126521</ArticleId><ArticleId IdType="pubmed">35620593</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>